Google News - Neuroscience - Neuroscience

New applied cognitive neuroscience course offered at RIT

Designed for students who want to learn how animals transform light and other radiation into information, the Animal Vision course explores the varied approaches to visually acquiring information employed by animals.

ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news

New white paper outlines the opportunity for next-generation drug candidates with greater selectivity for toxic amyloid beta oligomers

Minerva Neurosciences Inc (NASDAQ:NERV) Short Interest Update

Minerva Neurosciences Inc (NASDAQ:NERV) saw a large increase in short interest in November. As of November 29th, there was short interest totalling 3,630,000 shares, an increase of 12.7% from the November 14th total of 3,220,000 shares. Based on an average daily trading volume, of 385,100 shares, the days-to-cover ratio is presently 9.4 days. Currently, 11.2% […]

Minerva Neurosciences (NASDAQ:NERV) Rating Increased to Strong-Buy at BidaskClub

Minerva Neurosciences (NASDAQ:NERV) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Friday, BidAskClub reports. A number of other brokerages have also commented on NERV. Zacks Investment Research lowered shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Tuesday, October […]

Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease

/PRNewswire/ -- Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round — led by Domain Associates and Axon Ventures and...

Accelerating Neuroscience-focused Ion Channel Drug Discovery

Metrion and LifeArc have announced an extension of their neuroscience-focused ion channel drug discovery collaboration, following the success of the initial twelve-month agreement.

JFK Neuroscience Institute uses nerve stimulator to relieve patients' migraines

The JFK Neuroscience Institute in Edison is working with new technology to provide relief for migraine sufferers.

Minerva Neurosciences Inc (NASDAQ:NERV) Stake Reduced by Morgan Stanley

Morgan Stanley reduced its position in shares of Minerva Neurosciences Inc (NASDAQ:NERV) by 31.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,104 shares of the biopharmaceutical company’s stock after selling 2,374 shares during the period. Morgan Stanley’s holdings in Minerva Neurosciences were […]

NVIDIA Stock Rises 3% - NVIDIA (NASDAQ:NVDA) Stock rose by 3.06% to trade at $223.96 by 15:43 (20:43 GMT) on Thursday on the NASDAQ exchange.

Global Neuroscience Market Competitor Landscape, Growth, Opportunity Analysis,Trends & Forecast 2019-2024

The Neuroscience market has continued to have solid performance amidst a number of dynamic forces shaping the Neuroscience market, such as a potential trade war, skilled talent shortages, and straining supply chains. . Global Neuroscience Market Report is a professional and comprehensive research re

Minerva Neurosciences Inc (NASDAQ:NERV) Sees Large Growth in Short Interest

Minerva Neurosciences Inc (NASDAQ:NERV) saw a large growth in short interest in the month of November. As of November 29th, there was short interest totalling 3,630,000 shares, a growth of 12.7% from the November 14th total of 3,220,000 shares. Approximately 11.2% of the company’s shares are short sold. Based on an average daily trading volume, […]

Analysts Expect Minerva Neurosciences Inc (NASDAQ:NERV) to Post -$0.41 EPS

Wall Street brokerages expect Minerva Neurosciences Inc (NASDAQ:NERV) to post earnings per share (EPS) of ($0.41) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Minerva Neurosciences’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.36). Minerva Neurosciences posted earnings per share of ($0.34) in the […]

The Neuroscience of Psychedelic Drugs: Ending Psychedelic Myths With Professor David Nutt

Professor David Nutt has never been afraid to stick his head above the parapet on the topic of drugs. His repeated calling-out of the failures of contemporary drug policy has seen him butt heads with academics and politicians alike. In this interview with Professor Nutt, we discuss pot, policy and the potential of psilocybin.